Details for New Drug Application (NDA): 022239
✉ Email this page to a colleague
The generic ingredient in SUMAVEL DOSEPRO is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-four suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for 022239
Tradename: | SUMAVEL DOSEPRO |
Applicant: | Endo Ventures Ltd |
Ingredient: | sumatriptan succinate |
Patents: | 3 |
Formulation / Manufacturing: | see details |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;SUBCUTANEOUS | Strength | EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) | ||||
Approval Date: | Jul 15, 2009 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Try a Trial | Patent Expiration: | Nov 22, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Try a Trial | Patent Expiration: | Jul 31, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
Patent: | ⤷ Try a Trial | Patent Expiration: | Dec 6, 2024 | Product Flag? | Y | Substance Flag? | Delist Request? |
Expired US Patents for NDA 022239
Complete Access Available with Subscription